218 patents
Page 9 of 11
Utility
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
26 Oct 20
The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.
Wenqing Yao, Colin Zhang, Meizhong Xu, Jincong Zhuo, Chunhong He
Filed: 1 Jan 19
Utility
Immunomodulator compounds and methods of use
19 Oct 20
Compositions and methods for inducing PD-L1 internalization are disclosed.
Liang Lu, Wenyu Zhu, Ding-Quan Qian, Kaijiong Xiao
Filed: 20 Dec 17
Utility
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
12 Oct 20
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 6 Feb 19
Utility
Carboxamide compounds and uses thereof
12 Oct 20
Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
Filed: 18 Feb 19
Utility
Heterocyclic compounds as immunomodulators
12 Oct 20
Liangxing Wu, Jingwei Li, Wenqing Yao, Chao Qi, Ding-Quan Qian, Fenglei Zhang
Filed: 1 Apr 19
Utility
Heterocyclic compounds as LSD1 inhibitors
12 Oct 20
Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
Filed: 6 Mar 18
Utility
Heterocyclic compounds as immunomodulators
5 Oct 20
Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
Filed: 7 Mar 19
Utility
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
21 Sep 20
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 20 Oct 19
Utility
Topical formulation for a JAK inhibitor
31 Aug 20
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 9 Sep 19
Utility
Indazole compounds and uses thereof
24 Aug 20
Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
Filed: 18 Feb 19
Utility
Indazole compounds and uses thereof
17 Aug 20
Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Wenqing Yao
Filed: 18 Feb 19
Utility
Bicyclic heterocycles as FGFR4 inhibitors
10 Aug 20
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
Filed: 2 Jan 19
Utility
Imidazotriaines and imidazopyrimidines as kinase inhibitors
10 Aug 20
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
Filed: 19 Mar 18
Utility
Tertiary alcohols as PI3K-γ inhibitors
10 Aug 20
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
Filed: 16 Oct 18
Utility
Cyanoindazole compounds and uses thereof
27 Jul 20
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Onur Atasoylu, Hai Fen Ye, Kai Liu, Ke Zhang, Wenqing Yao
Filed: 6 Sep 18
Utility
Salts of an LSD1 inhibitor
27 Jul 20
The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
Filed: 19 Jun 19
Utility
Heterocyclic compounds and uses thereof
27 Jul 20
The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.
Jun Pan, Xiaozhao Wang, Joseph Barbosa, Wenqing Yao, Yingda Ye
Filed: 11 Aug 16
Utility
Cyclopropylamines as LSD1 inhibitors
20 Jul 20
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Chunhong He, Wenqing Yao, Fenglei Zhang
Filed: 18 Nov 18
Utility
Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
29 Jun 20
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Taisheng Huang, Chu-Biao Xue
Filed: 31 May 18
Utility
Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
8 Jun 20
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.
Peggy A. Scherle, Xuesong Liu
Filed: 26 Jul 18